dipyridamole has been researched along with Deficiency of GP 2b 3a Complex in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, BH | 1 |
| Castaldi, PA | 1 |
1 other study available for dipyridamole and Deficiency of GP 2b 3a Complex
| Article | Year |
|---|---|
Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets.
Topics: Adenosine Diphosphate; Antibodies; Aspirin; Bernard-Soulier Syndrome; Dipyridamole; Heparin; Humans; | 1986 |